Ann Rheum Dis:银屑病关节炎中滑膜组织多功能T细胞与DAPSA的关联

2019-01-10 xiangting MedSci原创

这些数据证明,PsA滑膜组织中多功能T细胞的富集与DAPSA和离体治疗反应密切相关。

这项研究探讨了银屑病关节炎(PsA)滑膜组织的多功能T细胞及其与临床疾病的关联和对治疗的意义。

酶解/机械性消化PsA滑膜组织以产生滑膜组织单细胞悬浮液。使用CD161作为Th17适应性的标志物,通过流式细胞术在匹配的PsA滑膜组织和外周血中测定多功能CD4、CD8、T辅助细胞1(Th1)、Th17和exTh17细胞频率。评估滑膜T细胞多功能性与银屑病关节炎疾病活动性(DAPSA)中关联,以及使用当前治疗模式,磷酸二酯酶4(PDE4)抑制剂培养的滑膜细胞悬浮液中的滑膜T细胞多功能性。

CD4+ T细胞浸润的PsA滑膜组织表达较高水平的白介素(IL)-17A、干扰素γ(IFN-γ)、GM-CSF和CD161,同时Th1、Th17和exTh17 T辅助细胞亚群富集(p均<0.05)。有趣的是,与匹配的血液相比,很大比例的滑膜T细胞亚群对GM-CSF、肿瘤坏死因子(-TNF)、-IL-17或IFN-γ呈三阳性(p均<0.05)。重要的是,多功能T细胞频率与DAPSA相关:Th1-GM-CSF+/TNF+/ IFN-γ+(r=0.7,p<0.01)、Th17-GM-CSF+/TNF+/ IL-17+(r=0.6,p<0.057)和exTh17-GM-CSF+/TNF+/ IFN-γ+(r=0.7,p=0.0096),没有观察到与产生单细胞因子的T细胞有关联。离体培养PsA滑膜组织细胞悬浮液后,产生GM-CSF+TNFα+IL-17A+或/IFN-γ+的多功能T细胞(p<0.05)被PDE4抑制剂所抑制,而不是产生单细胞因子的T细胞。

这些数据证明,PsA滑膜组织中多功能T细胞的富集与DAPSA和离体治疗反应密切相关。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2012909, encodeId=3a602012909b0, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jan 20 02:37:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265886, encodeId=a26912658862d, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sat Jan 12 01:37:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271074, encodeId=2b0f12e1074d4, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Jan 12 01:37:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482827, encodeId=e3f2148282e86, content=<a href='/topic/show?id=f91e2694e8' target=_blank style='color:#2F92EE;'>#APS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2694, encryptionId=f91e2694e8, topicName=APS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee0c7842002, createdName=12498bd5m18暂无昵称, createdTime=Sat Jan 12 01:37:00 CST 2019, time=2019-01-12, status=1, ipAttribution=)]
    2019-01-20 cmj8wellington

    #Dis#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2012909, encodeId=3a602012909b0, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jan 20 02:37:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265886, encodeId=a26912658862d, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sat Jan 12 01:37:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271074, encodeId=2b0f12e1074d4, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Jan 12 01:37:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482827, encodeId=e3f2148282e86, content=<a href='/topic/show?id=f91e2694e8' target=_blank style='color:#2F92EE;'>#APS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2694, encryptionId=f91e2694e8, topicName=APS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee0c7842002, createdName=12498bd5m18暂无昵称, createdTime=Sat Jan 12 01:37:00 CST 2019, time=2019-01-12, status=1, ipAttribution=)]
    2019-01-12 lmm397
  3. [GetPortalCommentsPageByObjectIdResponse(id=2012909, encodeId=3a602012909b0, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jan 20 02:37:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265886, encodeId=a26912658862d, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sat Jan 12 01:37:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271074, encodeId=2b0f12e1074d4, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Jan 12 01:37:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482827, encodeId=e3f2148282e86, content=<a href='/topic/show?id=f91e2694e8' target=_blank style='color:#2F92EE;'>#APS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2694, encryptionId=f91e2694e8, topicName=APS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee0c7842002, createdName=12498bd5m18暂无昵称, createdTime=Sat Jan 12 01:37:00 CST 2019, time=2019-01-12, status=1, ipAttribution=)]
    2019-01-12 zhaozhouchifen

    #PSA#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2012909, encodeId=3a602012909b0, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Jan 20 02:37:00 CST 2019, time=2019-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1265886, encodeId=a26912658862d, content=<a href='/topic/show?id=57a53011364' target=_blank style='color:#2F92EE;'>#关节炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30113, encryptionId=57a53011364, topicName=关节炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f90281, createdName=lmm397, createdTime=Sat Jan 12 01:37:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271074, encodeId=2b0f12e1074d4, content=<a href='/topic/show?id=4cfa14e8911' target=_blank style='color:#2F92EE;'>#PSA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14789, encryptionId=4cfa14e8911, topicName=PSA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Jan 12 01:37:00 CST 2019, time=2019-01-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1482827, encodeId=e3f2148282e86, content=<a href='/topic/show?id=f91e2694e8' target=_blank style='color:#2F92EE;'>#APS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2694, encryptionId=f91e2694e8, topicName=APS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee0c7842002, createdName=12498bd5m18暂无昵称, createdTime=Sat Jan 12 01:37:00 CST 2019, time=2019-01-12, status=1, ipAttribution=)]
    2019-01-12 12498bd5m18暂无昵称

    #APS#

    0